Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Department of Pharmacy, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Eur J Med Chem. 2017 Sep 8;137:30-44. doi: 10.1016/j.ejmech.2017.05.024. Epub 2017 May 8.
The design, synthesis, and SAR study of a new series of HIV-1 protease inhibitors incorporating stereochemically defined tetrahydrofuran-tertiary amine-acetamide P2-ligand are described. Various substituent effects on the tertiary amine P2-ligand and phenylsulfonamide P2'-ligand were investigated to maximize the ligand-binding site interactions in the protease active site. Most of inhibitors displayed low nanomolar to subnanomolar inhibitory potency. Inhibitor 20e containing N-(S-tetrahydrofuran)-N-(2-methoxyethyl)acetamide as P2-ligand along with 4-methoxylphenylsulfonamide as P2'-ligand displayed the most potent enzyme inhibitory activity (IC = 0.35 nM) and remarkably low cytotoxicity (CC = 305 μM).
本研究描述了一系列新型 HIV-1 蛋白酶抑制剂的设计、合成和构效关系研究,这些抑制剂包含了立体定义的四氢呋喃-叔胺-乙酰胺 P2-配体。研究了各种取代基对叔胺 P2-配体和苯磺酰胺 P2'-配体的影响,以最大限度地提高蛋白酶活性部位的配体结合部位相互作用。大多数抑制剂表现出低纳摩尔至亚纳摩尔的抑制活性。含有 N-(S-四氢呋喃)-N-(2-甲氧基乙基)乙酰胺作为 P2-配体以及 4-甲氧基苯磺酰胺作为 P2'-配体的抑制剂 20e 表现出最强的酶抑制活性(IC = 0.35 nM)和极低的细胞毒性(CC = 305 μM)。